Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques-Eric Gottenberg

Showing results (251-260 of 311) with videos related to

Pageof 32
Sort By:
Clinical and Experimental Rheumatology|August 30, 2019
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Manuel Ramos-Casals, Alexandre Maria, María E Suárez-Almazor, et al.
Joint Bone Spine|November 19, 2018
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritisPhilippe Mertz, Alexandre Belot, Ricard Cervera, et al.
Plos One|May 30, 2013
Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohortJacques-Eric Gottenberg, Raphaèle Seror, Corinne Miceli-Richard, et al.
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 21, 2022
Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ LocusDiana Trutschel, Pierre Bost, Xavier Mariette, et al.
Joint Bone Spine|February 22, 2021
Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)Camille Villon, Laure Orgeolet, Anne-Marie Roguedas, et al.
RMD Open|March 15, 2024
Concordance and agreement between different activity scores in polymyalgia rheumaticaJustine D'Agostino, Aghiles Souki, Anne Lohse, et al.
Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2025
Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumaticaBaptiste Chevet, Aghiles Souki, Emmanuel Nowak, et al.
Pageof 32

Showing results (251-260 of 311) with videos related to

Sort By:
Pageof 32
Clinical and Experimental Rheumatology|August 30, 2019
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Manuel Ramos-Casals, Alexandre Maria, María E Suárez-Almazor, et al.
Joint Bone Spine|November 19, 2018
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritisPhilippe Mertz, Alexandre Belot, Ricard Cervera, et al.
Plos One|May 30, 2013
Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohortJacques-Eric Gottenberg, Raphaèle Seror, Corinne Miceli-Richard, et al.
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 21, 2022
Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ LocusDiana Trutschel, Pierre Bost, Xavier Mariette, et al.
Joint Bone Spine|February 22, 2021
Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)Camille Villon, Laure Orgeolet, Anne-Marie Roguedas, et al.
RMD Open|March 15, 2024
Concordance and agreement between different activity scores in polymyalgia rheumaticaJustine D'Agostino, Aghiles Souki, Anne Lohse, et al.
Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2025
Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumaticaBaptiste Chevet, Aghiles Souki, Emmanuel Nowak, et al.
Pageof 32